Sun Pharma appoints Kirti Ganorkar as the Managing Director
Dilip Shanghvi to continue as the Executive Chairman of the Board
Dilip Shanghvi to continue as the Executive Chairman of the Board
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Subscribe To Our Newsletter & Stay Updated